NovaBay Pharmaceuticals to Present at Rodman & Renshaw 19th Annual Global Investment Conference
September 05 2017 - 6:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a
biopharmaceutical company focusing on commercializing prescription
Avenova® lid and lash hygiene for the domestic eye care market,
announces that Chief Financial Officer Jack McGovern is scheduled
to present a corporate overview at the Rodman & Renshaw 19th
Annual Global Investment Conference on Tuesday, September 12th,
2017, at 2:10 p.m. Eastern time (11:10 a.m. Pacific time). The
conference is being held at the New York Palace Hotel in New York
City.
A live webcast and replay will be available on the Investors
section of the Company's website at
http://novabay.com/investors/events.
About Avenova®
Avenova is NovaBay Pharmaceuticals’ main commercial focus. Data
from a multicenter clinical study show that Avenova reduced
bacterial load, the underlying cause of blepharitis, on ocular skin
surface by more than 90%. Laboratory tests show that hypochlorous
acid has potent antimicrobial activity in solution yet is non-toxic
to mammalian cells and also neutralizes bacterial toxins. Avenova
is marketed to optometrists and ophthalmologists throughout the
U.S. by NovaBay’s direct salesforce. It is accessible from more
than 90% of retail pharmacies in the U.S. through agreements with
McKesson Corporation, Cardinal Health and AmerisourceBergen.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, NEUTROPHASE® for wound care
market, and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
Stay informed on NovaBay's
progress:
Download our Mobile InvestorApp from the Apple
Store or Google PlayLike us on
FacebookFollow us on TwitterConnect with
NovaBay on LinkedInJoin us on
Google+Visit NovaBay's Website
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170905005199/en/
NovaBay ContactsFor NovaBay
Avenova purchasing information, please contact:Email usCall us:
1-800-890-0329www.Avenova.comorFrom the
CompanyJack McGovernChief Financial
Officer510-899-8800jmcgovern@novabay.comorInvestor Contact:LHA Investor RelationsJody
Cain310-691-7100Jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Sep 2023 to Sep 2024